Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya

Mutation patterns of resistance genes for... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/11-962" }, "headline": "Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous...", "datePublished": "2022-08-19T14:47:52", "dateModified": "2023-04-03T18:08:52", "author": [ { "@type": "Person", "name": "Zakayo Mwangi" }, { "@type": "Person", "name": "Grace Naeku" }, { "@type": "Person", "name": "Marianne Mureithi" }, { "@type": "Person", "name": "Frank Onyambu" }, { "@type": "Person", "name": "Wallace Bulimo" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": "Background: Non-tuberculous mycobacteria (NTM) treatment constitutes a macrolide-based antibiotic regimen in combination with aminoglycosides for Rapid-Growing Mycobacteria (RGM), and rifampicin for Slow-Growing Mycobacteria (SGM). Mutations in the anti-NTM drug target regions promote NTM evolution to mutant strains that are insusceptible to NTM drugs leading to treatment failure. We, therefore, described the mutation patterns of anti-NTM drug target genes including rrl, rrs, and rpoB in NTM isolates from Kenya. Methods: We carried out a cross-sectional study that included 122 NTM obtained from the sputum of symptomatic tuberculosis-negative patients in Kenya. All 122 NTM underwent targeted sequencing of the rrl gene. The 54 RGM were also sequenced for rrs, and the 68 SGM were sequenced for rpoB genes using ABI 3730XL analyzer. The obtained sequences were aligned to their wild-type reference sequences for each gene using Geneious then mutations were identified. Pearson chi-square at a 95% confidence interval tested the association of NTM to mutation patterns for each gene. Results: NTM harboring mutations associated with resistance to at least one of the antibiotics used in the macrolide-based therapy were 23% (28/122). Of these NTM, 10.4% (12/122) had mutations in the rrl gene with 58.3% (7/12) comprising RGM and 41.7% (5/12) being SGM. Mutation at position 2058 (A2058G, A2058C, A2058T) of the rrl gene was seen for 83.3% (10/12) of NTM, while 16.6% (2/12) harbored a A2059G mutation. Of the 54 RGM included for rrs characterization, 11.1% (6/54) exhibited mutations at position 1408(A1408G), while 14.7% (10/68) of the SGM had mutations in the rpoB gene at positions S531W, S531L, S531Y, F506L, E509H with M.gastri having multiple mutations at positions D516V, H526D and, S531F. Conclusion: We demonstrated a significant level of mutations associated with drug resistance for macrolides, aminoglycosides, and rifampicin in NTM isolated from symptomatic TB negative patients in Kenya." } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/11-962", "name": "Mutation patterns of resistance genes for macrolides, aminoglycosides,..." } } ] } Home Browse Mutation patterns of resistance genes for macrolides, aminoglycosides,... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Mwangi Z, Naeku G, Mureithi M et al. Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.12688/f1000research.124002.5 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article Revised Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] Previously titled: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in nontuberculous mycobacteria isolates from Kenya Zakayo Mwangi 1,2 , Grace Naeku 3 , Marianne Mureithi 1 , Frank Onyambu https://orcid.org/0000-0002-1195-8762 2,4 , Wallace Bulimo https://orcid.org/0000-0001-8475-0586 5 Zakayo Mwangi 1,2 , Grace Naeku 3 , [...] Marianne Mureithi 1 , Frank Onyambu https://orcid.org/0000-0002-1195-8762 2,4 , Wallace Bulimo https://orcid.org/0000-0001-8475-0586 5 PUBLISHED 03 Apr 2023 Author details Author details 1 Department of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Nairobi, 30197, Kenya 2 Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, Meru, 972, Kenya 3 Molecular and Infectious Disease Research Laboratory, University of Nairobi, Nairobi, Nairobi, 30197, Kenya 4 Centre for Molecular Biosciences and Genomics, Centre for Molecular Biosciences and Genomics, Nairobi, Nairobi, 29408, Kenya 5 Kenya Medical Research Institute, Kenya Medical Research Institute, Nairobi, Nairobi, 54840, Kenya Zakayo Mwangi Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing Grace Naeku Roles: Investigation, Writing – Review & Editing Marianne Mureithi Roles: Supervision, Writing – Review & Editing Frank Onyambu Roles: Conceptualization, Methodology, Supervision, Writing – Review & Editing Wallace Bulimo Roles: Conceptualization, Methodology, Supervision, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS This article is included in the Cell & Molecular Biology gateway. Abstract Background: Non-tuberculous mycobacteria (NTM) treatment constitutes a macrolide-based antibiotic regimen in combination with aminoglycosides for Rapid-Growing Mycobacteria (RGM), and rifampicin for Slow-Growing Mycobacteria (SGM). Mutations in the anti-NTM drug target regions promote NTM evolution to mutant strains that are insusceptible to NTM drugs leading to treatment failure. We, therefore, described the mutation patterns of anti-NTM drug target genes including rrl , rrs , and rpoB in NTM isolates from Kenya. Methods: We carried out a cross-sectional study that included 122 NTM obtained from the sputum of symptomatic tuberculosis-negative patients in Kenya. All 122 NTM underwent targeted sequencing of the rrl gene. The 54 RGM were also sequenced for rrs , and the 68 SGM were sequenced for rpoB genes using ABI 3730XL analyzer. The obtained sequences were aligned to their wild-type reference sequences for each gene using Geneious then mutations were identified. Pearson chi-square at a 95% confidence interval tested the association of NTM to mutation patterns for each gene. Results: NTM harboring mutations associated with resistance to at least one of the antibiotics used in the macrolide-based therapy were 23% (28/122). Of these NTM, 10.4% (12/122) had mutations in the rrl gene with 58.3% (7/12) comprising RGM and 41.7% (5/12) being SGM. Mutation at position 2058 (A2058G, A2058C, A2058T) of the rrl gene was seen for 83.3% (10/12) of NTM, while 16.6% (2/12) harbored a A2059G mutation. Of the 54 RGM included for rrs characterization, 11.1% (6/54) exhibited mutations at position 1408(A1408G), while 14.7% (10/68) of the SGM had mutations in the rpoB gene at positions S531W, S531L, S531Y, F506L, E509H with M.gastri having multiple mutations at positions D516V, H526D and, S531F. Conclusion: We demonstrated a significant level of mutations associated with drug resistance for macrolides, aminoglycosides, and rifampicin in NTM isolated from symptomatic TB negative patients in Kenya. READ ALL READ LESS Keywords Nontuberculous mycobacteria, slow-growing mycobacteria, rapid-growing mycobacteria, macrolides, aminoglycosides, rifampicin Corresponding Author(s) Zakayo Mwangi ( [email protected] ) Close Corresponding author: Zakayo Mwangi Competing interests: No competing interests were disclosed. Grant information: This work was supported by the Meru University of Science and Technology 6th call for proposals awarded to Zakayo M Mwangi. The content is solely the responsibility of the authors and does not represent the views of the funders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2023 Mwangi Z et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Mwangi Z, Naeku G, Mureithi M et al. Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.12688/f1000research.124002.5 ) First published: 19 Aug 2022, 11 :962 ( https://doi.org/10.12688/f1000research.124002.1 ) Latest published: 03 Apr 2023, 11 :962 ( https://doi.org/10.12688/f1000research.124002.5 ) Revised Amendments from Version 4 Title: Inclusion of a hyphen in Non-tuberculous Abstract: Inclusion of a hyphen in Non-tuberculous Mycobacterium (NTM). Used upper case for the first letters of the acronym SGM and RGM. In the results section, the percentage are outside the brackets while proportions have been indicated in brackets. For mutations, nucleotide change has been indicated for each position. Introduction: Details of Lowenstein Jensen media for growth of mycobacteria has been included. Second paragraph, the duration of treatment of NTM infections has been indicated. indication that Rifampicin is recommended for first-line treatment of MTB alongside other drugs. Laboratory procedures: Sputum sample estimate volume for each participant has been provided. Details on FM microscopy readers and reviewers is now indicated Results: The table with results indicating that the bulk of the samples were obtained from Lake Victoria, Coastal and Nairobi region has been mentioned. Discussion: rrl significant mutations are critically discussed and their relevance to macrolide drug resistance Title: Inclusion of a hyphen in Non-tuberculous Abstract: Inclusion of a hyphen in Non-tuberculous Mycobacterium (NTM). Used upper case for the first letters of the acronym SGM and RGM. In the results section, the percentage are outside the brackets while proportions have been indicated in brackets. For mutations, nucleotide change has been indicated for each position. Introduction: Details of Lowenstein Jensen media for growth of mycobacteria has been included. Second paragraph, the duration of treatment of NTM infections has been indicated. indication that Rifampicin is recommended for first-line treatment of MTB alongside other drugs. Laboratory procedures: Sputum sample estimate volume for each participant has been provided. Details on FM microscopy readers and reviewers is now indicated Results: The table with results indicating that the bulk of the samples were obtained from Lake Victoria, Coastal and Nairobi region has been mentioned. Discussion: rrl significant mutations are critically discussed and their relevance to macrolide drug resistance See the authors' detailed response to the review by Leena Al-Hassan See the authors' detailed response to the review by Utpal Sengupta See the authors' detailed response to the review by Clement Likhovole READ REVIEWER RESPONSES Introduction Non-tuberculous Mycobacteria (NTM) are a group of about 170 Mycobacteria species that do not include Mycobacterium tuberculosis and Mycobacterium leprae ( Falkinham, 2017 ; Koh et al. , 2006 ; Peixoto et al. , 2020 ; Sam et al. , 2020 ; Simons et al. , 2011 ). In mycobacterial culture using Lowestein-Jensen (LJ) media which is a solid selective media for mycobacteria, NTM varies in their growth characteristics, with Rapid Growing Mycobacteria (RGM) forming visible colonies within seven days of incubation and Slow-Growing Mycobacteria (SGM) taking up to fourty days. SGM include Mycobacterium avium complex (MAC), Mycobacterium chimaera , Mycobacterium kansasii , Mycobacterium malmoense , and Mycobacterium xenopi , whereas RGM comprise species from the Mycobacterium abscessus and Mycobacterium fortuitum complexes ( Alffenaar et al. , 2021 ). In human infections, identifying NTM is crucial for determining clinically relevant species and the best treatment plan ( Chalmers et al. , 2019 ; Mwangi et al. , 2022a ). NTM treatment consists of a macrolide-based antibiotic regimen which include clarithromycin or azithromycin, combined with other selected antibiotics which are given for 12 to 18 months until culture negativity is achieved. ( Falkinham, 2018 ). In addition to macrolides, the antibiotic of choice is largely determined by the infecting NTM, its growth rate, and the intricacy of the mycolic acid cell wall ( Goswami et al. , 2016 ). Rifampicin and ethambutol are also used in SGM treatment, while aminoglycosides, cefoxitin, imipenem, or tigecycline are used in RGM treatment ( Brown-Elliott et al. , 2012 ; Saxena et al. , 2021 ). Due to the slow growth of NTM compared to other bacterial infections, antimicrobial combination therapy is strongly recommended in NTM treatment to avoid the development of drug resistance ( Falkinham, 2018 ; Pharmd et al. , 2019 ). The antibiotic regimen of patients with pre-existing lung diseases including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and bronchiectasis or with immunodeficiencies are the same as for patients without these comorbidities ( Koh, 2017 ). Anti-mycobacterial drugs attach to their binding sites with a high affinity, preventing the target gene product from functioning normally ( Alffenaar et al. , 2021 ). Changes in the structure of the target regions caused by mutations, on the other hand, interfere with the medications' ability to attach to them, resulting in antibiotic resistance. As a result, determining the antibiotic resistance profile of NTM is critical for determining an effective treatment strategy for a specific NTM infection ( Goswami et al. , 2016 ; Nasiri et al. , 2017 ). Acquired resistance to anti-NTM drugs develops due to mutations in the NTM drug target regions, subsequently promoting NTM evolution to mutant strains that are insusceptible to anti-NTM drugs ( Huh et al. , 2019 ; Munita & Arias, 2016 ; Nasiri et al. , 2017 ; Pharmd et al. , 2019 ; Saxena et al. , 2021 ). Prolonged exposure to NTM antibiotics, as seen in the lengthy NTM regimen, sub-optimal administration of anti-NTM drugs, as seen in patients who do not adhere to the regimen or who are lost to follow up, and incorrect prescription for NTM infection due to NTM misdiagnosis all promote mutation in the drug target regions ( Gopalaswamy et al. , 2020 ; Munita & Arias, 2016 ; Zhou et al. , 2020 ). Macrolides inhibit protein synthesis by binding to the peptide exit tunnel of ribosomes, hence preventing the growing peptide chain from exiting the peptidyl transferase center of the ribosome ( Hansen et al. , 2002 ). Mutation of the rrl gene at positions A2058 and A2059 accounts for 80-100% of the macrolide resistance in NTM. Macrolide resistance can also be conferred by the erm (41) gene which encodes a ribosomal methyltransferase that methylates the rrl thus blocking the drug-binding site of the macrolide ( Bastian et al. , 2011 ; Huh et al. , 2019 ). Aminoglycosides inhibit protein synthesis by binding the bacterial 30S ribosomal subunit interfering with bacterial protein translation and leading to cell death ( Saxena et al. , 2021 ). Drug resistance to aminoglycosides is associated with modification in the rrs gene mainly observed as point mutation at position 1408 ( Brown-Elliott et al. , 2013 ). In addition, mutations at positions 1406, 1409, and 1491 have been shown to confer resistance to aminoglycosides in some NTM ( Olivier et al. , 2017 ). Rifampicin is a key drug in treating mycobacterial diseases. It is the recommended first line drug for treatment of M. tuberculosis alongside other drugs ( WHO, 2014 ). It inhibits the synthesis of Ribonucleic acid (RNA) by binding to the ß-subunit of the RNA polymerase that is encoded by rpoB gene. Most rifampicin-resistant mycobacteria have mutations in an 81-bp rifampicin resistance determining region (RRDR) within the rpoB gene. Mutations in this region account for 95% of rifampicin resistance in mycobacteria. The commonly observed mutations within the RRDR of rpoB are often seen at codons 526, and 531 ( Li et al. , 2016 ). M. kansasii has also shown mutation conferring resistance to rifampicin at codons 513 and 516, while MAC also shows resistance to rifampicin with mutations outside the RRDR at codon 626 (K626T) ( Ramasoota et al. , 2006 ). Detection of drug resistance in NTM can be carried out by drug susceptibility testing (DST) through broth microdilution, ( Litvinov et al. , 2018 ; Park et al. , 2020 ), sequencing for mutations in the rrl, rrs and rpoB genes ( Brown-Elliott et al. , 2012 ; Huh et al. , 2019 ; Saxena et al. , 2021 ), or by using GenoType NTM-DR test (Hain, Lifescience, Nehren, Germany) which is a line probe assay (LPA) that detects resistance to macrolides and aminoglycosides ( Bouzinbi et al. , 2020 ). We, therefore, investigated drug resistance in NTM by describing the mutation patterns in rrl , rrs , and rpoB genes for macrolides, aminoglycosides and rifampicin respectively, in NTM isolated from symptomatic TB-negative patients from Kenya. Methods We carried out a cross-sectional study that included 122 NTM identified by mycobacterial culture and hsp65 targeted sequencing from the sputum of symptomatic TB-negative patients ( Mwangi et al. , 2022a ). The patients had provided approximately 5 ml of sputum to the National Tuberculosis Reference Laboratory (NTRL) in Kenya between January to November 2020. In this study, the 122 NTM including 54 RGM and 68 SGM underwent targeted sequencing of the rrl gene. The RGM were also sequenced for rrs , and the SGM were sequenced for rpoB genes using ABI 3730XL analyzer (Applied Biosystems, Foster City, California, USA). Laboratory procedures Sample processing, mycobacterial culture and growth identification The sputum samples were decontaminated using the N-acetyl-L-cysteine 2% NaOH (NALC-NaOH) procedure, then inoculated into Mycobacteria Growth Indicator Tube (MGIT) and Lowestein-Jenseen (LJ) medias, incubated at 37°C and monitored for growth for up to eight weeks respectively. At the same time, sputum smears were prepared, air dried, heat fixed then fluorochrome stained with auramine O where mycobacteria appeared as bright yellow fluorescent rods when viewed under a light emitting diodes (LED) microscope. Fluorescent microscopy was performed by NTRL laboratory technologist then smears were reviewed by the section head before reporting. The culture growth in MGIT and LJ underwent the Mtb identification testing using the SD Bioline TB Ag MPT64 assay (capilia) (Standard Diagnostics, Yongin-si, Gyeonggi-do, Republic of Korea) and capilia positive samples were excluded from the study. The capilia negative samples underwent ZN microscopy with presence of AFB indicating a possible NTM. DNA extraction Mycobacterial DNA was extracted from 500 μL of re-suspended colonies using using Geno Lyse ® ( Hain Lifescience, Nehren, Germany) according to the manufacturer's instructions. Briefly, 100 ul of lysis buffer (A-LYS) buffer was added to each cryovial containing the resuspended colonies and incubated for five minutes at 95 o C after which 100 ul neutralization buffer (A-NB) was added and centrifugation done at 5000G for ten minutes. The supernatant was transferred to a newly labelled cryovial awaiting PCR. Conventional PCR, DNA gel electrophoresis and DNA purification Conventional PCR targeting rrl, rpoB and rrs genes of NTM were conducted using the Horse-Power™ Taq DNA Polymerase MasterMix (Canvax, Córdoba, Spain) in a final reaction volume for each gene of 13 μl comprising 6.25 μl of 2X Horse-Power™ Taq DNA Polymerase MasterMix, 2.5 μl DNA template, 0.25 μl of each of both forward and reverse primers ( Table 1 ) at a final concentration of 10 pmoles, and 3.75 μl of nuclease-free water to make up the reaction volume. The PCR assays were carried out with a Veriti Thermal Cycler (Applied Biosystems, Foster City, CA, USA) ( Table 1 ). Thermal cycling conditions for rrl were as follows: one cycle of 95°C for five minutes, 35 cycles of 95°C for one minute, 55°C for one minute, 72°C for one minute, and a final extension for ten minutes at 72°C. PCR for rrs was conducted as follows 95°C for five minutes, 35 cycles of 95°C for one minute, 60°C for one minute, 72°C for one minute, and a final extension for seven minutes at 72°C. PCR for the rpoB was conducted as follows: 95°C for five minutes, 35 cycles of 95°C for one minute, 58°C for one minute, 72°C for one minute, and a final extension for seven minutes at 72°C. Amplified products were confirmed on a 1% Agarose gel stained with 4.6 μl SYBR safe DNA stain (Invitrogen, Carlsbad, California, USA), and results were visualized with an UltraViolet gel viewer (Terra Universal, S. Raymond Ave, Fullerton, CA , USA). For the corresponding runs, a positive control containing drug-resistant NTM with mutations in the rrl, rpoB and rrs genes was used, as well as a negative control containing drug sensitive NTM without mutations in the drug target genes were included. Table 1. Nucleotide sequence of primers for rrl , rpoB and rrs genes. Gene Primers Size Reference rrl F (5′-TTTAAGCCCCAGTAAACGGC-3′) R (5′-GTCCAGGTTGAGGGAACCTT-3′) 420 bp ( Park et al. , 2020 ) rpoB F (5′-GGCAAGGTCACCCCGAAGGG-3′) R (5′-AGCGGCTGCTGGGTGATCATC-3′) 723 bp ( Adékambi et al. , 2003 ) rrs F (5′-AAGGAGGTGATCCAGCCGCA-3′) R (5′-TCCCTTGTGGCCTGTGTGCA-3′) 341 bp ( Kim et al. , 2021 ) The PCR products were enzymatically purified using ExoSAP IT (Applied Biosystems, Foster City, California, USA). Purification conditions were done at 37°C for fifteen minutes followed by a second incubation at 80°C for fifteen minutes and a final cooling step at 4°C for five minutes. rrl, rpoB and rrs genes sequencing The purified amplicons were sequenced in the forward and reverse directions by Sanger sequencing using Big Dye™ Terminator Version 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, California, USA) and the forward and reverse primers. The sequencing reaction for each gene was a 10 μl reaction comprising 1.25 μl of Big Dye Terminator, 3 μl of 5× Sequencing Buffer, 1 μl of 1 pmol of the sequencing primer, and 1.5 μl of the PCR product. The reaction volume was made up by adding 3.25 μl of nuclease-free water. The reaction proceeded through 96°C for 1 minute then 25 cycles of 96°C for 10 seconds, 50°C for five seconds, and 60°C for four minutes. Purification of cycle-sequencing products was done using the BigDye X Terminator™ purification kit following the manufacturer’s instructions (Applied Biosystems, Foster City, California, USA) and purified products were loaded onto the ABI 3730 genetic analyzer (Applied Biosystems, Foster City, California, USA) for capillary electrophoresis. Data analysis The obtained sequences were first assembled into contigs and the consensus sequences aligned to their wild-type reference sequences for each gene using Geneious version 11.0 (Biomatters Ltd, Auckland, New Zealand). Mutations in the drug resistance genes were identified visually. STATA version 14 (StataCorp, College Station, Texas, USA) was used to test the association of NTM species to mutation patterns using Pearson chi-square at 95% confidence interval. Results Our study established that 23% (28/122) of NTM harbored mutations associated with resistance to at least one of the antibiotics in the macrolide-based therapy. One isolate (C47) containing M. abscessus had mutations conferring resistance in both rrl and rrs genes. The bulk of the isolates with mutations associated with drug resistance originated from the Lake Victoria, Coastal, and Nairobi regions, with 5% (6/122) NTM showing mutations in the rrl , rrs , or rpoB genes (p=0.012)) ( Table 2 ). The age group was statistically significant (p=0.012), with isolates from participants aged 21 to 35 years old having the highest (n=10, 35.7%) number of NTM with target gene alterations for rrl , rrs , and rpoB genes. Males accounted for 76.5% (21/28) of the NTM isolates with mutations in the drug target genes and indicated a strong statistical significance (p=0.000). The majority of NTM with these mutations were detected in new (n=8; 28.5%) and TB relapse patients (n=8; 28.5%) patients, which had a significant statistical significance (p=0.001) ( Table 2 ). Table 2. Sociodemographic characteristics of patients with drug-resistant NTM. Variables NTM (n, %) Genes with mutations associated with drug resistance to NTM P value rrl (n, %) rrs (n, %) rpoB (n, %) Regions Mt. Kenya 23(18.9) 2(16.7) - - North Rift Valley 13(10.7) 1(8.3) - - South Rift valley 9(7.3) 2(16.7) - 2(20) Lake Victoria 8(6.6) - 2 (33.3) 4(40) 0.012 Lower Eastern 8(6.6) 1(8.3) - 2(20) Coast 33(27) 2(16.7) 2 (33.3) 2(20) Northeastern 4(3.3) - - - Nairobi 24(19.6) 4(33.3) 2 (33.3) - Subtotal 122(100) 12 (100) 6 (100) 10(100) Age group 65 7(5.8) 1(8.3) 0 1(10 Subtotal 122(100) 12(100) 6(100) 10(100) Gender Female 32 (27) 4(33.3) 2 (33.3) 1(10) Male 90(73) 8(66.7) 4(66.7) 9(90) 0.000 Subtotal 122(100) 12(100) 6(100) 10(100) Type of patient New 33(27) 3(25) 2 (33.3) 3(30) Retreatment 21(17) 3(25) 1(16.7) 2(20) Relapse 30(25) 2(16.7) 2(33.3) 4(40) 0.001 MDR follow-up 38(31) 4(33.3) 1(16.7) 1(10) Subtotal 122(100) 12(100) 6(100) 10(100) Mutations in rrl gene for the NTM were highly significant with a p value of <0.001. Of the NTM with mutations in their drug target genes, 10.4% (12/122) had mutations in the rrl gene ( Table 2 ) with 58.3% (7/12) comprising RGM ( Table 3 ) and 41.7% (5/12) being SGM ( Table 3 ). Point mutation at position 2058 (A2058G, A2058C, A2058T) of the rrl gene was seen for 83.3% (10/12) of NTM including M.intracellulare , M. abscessus subsp abscessus, M. nebraskense, M. massiliense, M. kumamototense, M. heraklionense, and M. bourgelatii. A rrl A2059G mutation was seen for M. abscessus subsp abscessus representing16.6% (2/12) of the NTM ( Table 3 ). Table 3. NTM showing mutations associated with macrolide resistance. Isolate ID NTM species Growth rate Position of mutation in rrl X 2 , p value C21, C64 M. intracellulare SGM A2058G C31 M. nebraskense SGM A2058C C109 M. kumamototense SGM A2058T C132 M. heraklionense SGM A2058T C36, 63 M. abscessus subsp abscessus RGM A2058C 87, <0.001 C47 M. abscessus subsp abscessus RGM A2058G C88 M. massiliense RGM A2058T C133 M. bourgelatii RGM A2058C C46, C71 M. abscessus subsp abscessus RGM A2059G Of the 54 RGM included for rrs characterization, 11.1% (6/54) exhibited mutations at position 1408(A1408G), The NTM species presenting with these mutations include M. abscessus subsp abscessus, M. chelonae, and M. alsense ( Table 4 ). The NTM species had a low likelihood (p=0.06) of developing mutations in rrs gene for aminoglycoside resistance. Table 4. Rapid-growing NTM showing mutations associated with aminoglycoside resistance. Isolate ID NTM species Position of mutation in rrs X 2 , p value C12, C53 M. chelonae A1408G C58 M. alsense A1408G 25, 0.06 C46, C47, C70 M. abscessus subsp abscessus A1408G A low association (p=0.89) for rpoB mutation in SGM was observed. Mutations within codons between 503-533 of the rpoB were seen for 14.7% (10/68) of SGM. These SGM included M. avium subsp avium , (S531W S531L, S531Y) M. intracellulare (F506L), M. yongonense (E509H) and M. gastri which had multiple mutations at positions D516V, H526D and, S531F ( Table 5 ). Table 5. Slow- growing NTM showing mutations associated with rifampicin resistance. Isolate ID NTM species Codons with mutation in rpoB X 2 , p value C66 M. avium subsp avium S531W C78, C94 M. avium subsp avium S531L C128 M. avium subsp avium S531Y 26, 0.89 C10, C57, C64, C166 M. intracellulare F506L C74 M. yongonense E509H C151 M. gastri D516V, H526D, S531F Discussion Non‐tuberculous mycobacteria ( NTM ) are an important cause of pulmonary disease worldwide, and are being isolated increasingly ( Rivero-Lezcano & Carolina González-Cortés, 2019 ). They are often mistakenly treated as M. tuberculosis in countries devoid of laboratory competence for mycobacterial species differentiation ( Pokam et al. , 2022 ). Recently, there has been a considerable rise in infections caused by NTM ( Saxena et al. , 2021 ). These mycobacteria, which comprise a large and diverse range of species, have developed resistance to most conventional antibiotics, rendering their treatments unsatisfactory ( Brown-Elliott et al. , 2012 ). This study established that 23% of NTM harbored mutations associated with resistance to at least one of the antibiotics in the macrolide-based therapy. Regional distribution of NTM with mutations in the target genes had a significant correlation (p=0.012) with the bulk of the isolates originating from the Lake Victoria (n=6, 5%), Coastal (n=6, 5%), and Nairobi (n=6, 5%) regions. The observed regional diversity of NTM harboring drug resistance mutations across Kenya could be attributed to NTM evolution to evade natural antibiotics secreted as secondary metabolites by nearby environmental bacteria in various geographical landscapes (Moore et al. , 2019). The 21-35 years age group had the highest number of NTM isolates presenting with drug resistance associated mutations while males comprised the majority (n=21, 76.5%) of cases with NTM showing these mutations. These mutations were associated with a history of previous TB infection as seen in the high number of TB relapse cases recorded in this study (n=8; 28.5%, p=0.001). This is a common observation in sub-Saharan Africa given the high incidence of M. tuberculosis disease and the frequent misdiagnosis of NTM infection with TB seen in this region ( Aliyu et al. , 2013 ; Hoza et al. , 2016 ; Pokam et al. , 2022 ; Mwangi et al. , 2022a ). Despite NTM demonstrating high levels of resistance to a broad range of antibiotics, macrolides including clarithromycin, erythromycin, and azithromycin remain the most effective antibiotic with > 80% of isolates showing susceptibility ( Ananta et al. , 2018 ). However, some NTM including MAC and M. abscessus have been associated with increased resistance to macrolides leading to treatment failure ( Saxena et al. , 2021 ). The mechanisms of macrolide resistance have been studied at the molecular level and has consistently demonstrated that 80-100% of phenotypic macrolide resistant clinical isolates contained point mutations at positions A2058 and A2059 in the 23S rRNA gene for NTM ( Huh et al. , 2019 ). According to 23S rRNA crystallography investigations, A2058 and A2059 serve as important contact sites for macrolide binding since they are conveniently situated on the surface of the peptide exit tunnel of ribosomes. The architecture of the macrolide binding site is changed by a point mutation of A2058/A2059, which creates a smooth, sunken interaction surface that weakens the interaction of macrolides with their binding site hence leading to drug resistance ( Poehlsgaard et al. , 2005 ). Our study demonstrated that majority of macrolide-resistant isolates (88.3%) including M. intracellulare (A2058G), M. nebraskense (A2058C), M. massiliense (A2058T), M. kumamototense (A2058T), M. heraklionense (A2058T), and M. bourgelatii (A2058C) had a point mutation at position 2058 in the rrl, while two (16.7%) M. abscessus subsp abscessus isolates had mutation at position A2059G. The increased potential for development of these mutations in MAC species including M. intracellulare, and M. abscessus could be attributed to inherent factors such as a high propensity for genetic mutation in the drug target region, and high drug tolerance levels ( Park et al. , 2020 ), environmental factors facilitating the emergence of mutations in the rrl and gene subsequent ease of transmission to humans ( Beverley Cherie Millar, 2019 ). Other mutations that could confer resistance to macrolides include T2419 in M. intracellulare ( Huh et al. , 2019 ). However, this mutation was not demonstrated in the Kenyan isolates of this study. The commonly used aminoglycosides for the treatment of NTM are amikacin, streptomycin, kanamycin, tobramycin, and streptomycin ( Krause et al. , 2016 ). In our present study, three M. abscessus subsp abscessus , two M. chelonae, and one M. alsense presented with a A1408G mutation. Genotypic characteristics in rrs that are associated with aminoglycoside resistance usually are in concordance with DST broth microdilution and GenoType NTM-DR assays, implying that mutations within rrs are the molecular basis of aminoglycoside resistance in NTM ( Bouzinbi et al. , 2020 ). For instance, a study that selected in-vitro aminoglycoside-resistant M. abscessus and M. chelonae presented an A→G mutation at position 1408 within the rrs upon sequencing. This confirms that a single point mutation at 1408 is adequate to confer high-level aminoglycoside resistance ( Nessar et al. , 2011 ). Further, individual mutations at T1406, C1409 and G1491 have also indicated considerable resistance to aminoglycoside in most M. abscessus subspecies ( Nessar et al. , 2011 ). Similar to other bacteria, NTM present with low-level aminoglycoside resistance through the production of drug-modifying enzymes including acetyltransferases ( Sanz-García et al. , 2019 ), phosphorylases, adenylates, and methylases which act at various points on the aminoglycoside scaffold making it less potent ( Krause et al. , 2016 ; Munita & Arias, 2016 ; Sanz-García et al. , 2019 ; Tarashi et al. , 2022 ; Zaragoza Bastida et al. , 2017 ). Why does mutation at 1408 confer more drug resistance compared to other point mutation. Similar to M. tuberculosis , resistance to rifampicin in NTM is associated with mutations in the 81 bp RRDR corresponding to codons 503 to 533 of the rpoB gene ( Saxena et al. , 2021 ; Zhou et al. , 2020 ). Our study identified 11.6% (10/68) NTM with mutations occurring at codon 531 in M. avium, codon 506 in M. intracellulare , 509 in M. yongonense. M. gastri had amino acid substitutions at positions 516, 526, 531 of the rpoB gene. Our findings did not establish mutations outside of the RRDR. However, low-level rifampicin resistance has previously been demonstrated in M. intracellulare with mutations occurring outside the RRDR at position N494S ( Park et al. , 2020 ). Broth microdilution analysis which is the gold standard for rifampicin drug resistance testing presents a high minimum inhibition concentration (MIC) for isolates with mutations in the RRDR, hence confirming the role of these mutations in conferring high-level resistance to rifampicin ( Huh et al. , 2019 ). We further demonstrated that M. gastri harbored more than one mutation within the RRDR which is a unique attribute observed for M. kansasii complex species to which M.gastri belongs ( Wu et al. , 2018 ). A similar study obtained rifampicin-resistant M. kansasii from clinical isolates and in vitro generated mutant, and demonstrated mutations in codons 513, 526, and 531 of rpoB which is a common pattern in some SGM and M. tuberculosis ( Klein et al. , 2001 ). We found considerable levels of mutations in the drug target genes for macrolides, aminoglycosides and rifampicin in Kenyan NTM. To guide therapy, both species-level identification and drug resistance testing of NTM should be performed before starting treatment for NTM infection. Conclusion We demonstrated significant mutations associated with drug resistance for macrolides, aminoglycosides and rifampicin in NTM isolated from symptomatic TB-negative patients in Kenya. M. abscessus and MAC were the dominant NTM with rrl mutations, and most mutations occurred at position 2058. Majority of RGM had mutation at position 1408 of the rrs gene, while rpoB mutations presented within the RRDR. Limitations of the study This study investigated the acquired mechanisms of drug resistance for NTM. Other intrinsic factors apart from drug target gene mutation could influence the sensitivity of NTM to antibiotics. Despite this limitation, the study documents drug resistance-associated mutation patterns of Kenyan NTM for the first time, and advocates for drug resistance testing before commencement of treatment for NTM infection. Ethical clearance This study was approved by the Kenyatta National Hospital-University of Nairobi Ethics Review Committee (Ref: KNH-ERC/A/38) on 30 th January 2020. Waiver for individual informed consent was granted as the study utilized remnant clinical samples and the research posed no greater than minimal risk to the study subjects. Data availability Figshare. Mutation Patterns of Resistance Genes for Macrolides, Aminoglycosides, and Rifampicin in Non‐tuberculous Mycobacteria Isolates from Kenya. DOI: https://doi.org/10.6084/m9.figshare.20331378.v2 ( Mwangi et al. , 2022b ). This project contains the following underlying data: - Mutation patterns for rrl, rrs, and rpoB genes in NTM Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Author contributions ZMM - Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing GN - Investigation, Writing – Review & Editing MWM - Supervision, Writing- Review and Editing FGO - Conceptualization, Methodology, Supervision, Writing- Review and Editing WDB - Conceptualization, Methodology, Supervision, Writing- Review and Editing Acknowledgments We are grateful to the management of the National Public Health Laboratories- Kenya for granting us permission to access the National Tuberculosis Reference Laboratory and carry out this research. Much appreciation to the laboratory staff at the National Tuberculosis Reference. Laboratory for their technical support during the study's collection and initial analysis of sputum samples. References Adékambi T, Colson P, Drancourt M: rpoB-Based Identification of Nonpigmented and Late-Pigmenting Rapidly Growing Mycobacteria. J. Clin. Microbiol. 2003; 41 (12): 5699–5708. PubMed Abstract | Publisher Full Text | Free Full Text Alffenaar JW, Märtson AG, Heysell SK, et al. : Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. Clin. Pharmacokinet. 2021; 60 (6): 711–725. PubMed Abstract | Publisher Full Text Aliyu G, El-kamary SS, Abimiku A, et al. : Prevalence of Non-Tuberculous Mycobacterial Infections among Tuberculosis Suspects in Nigeria. PLoS One. 2013; 8 (5): e63170–e63177. PubMed Abstract | Publisher Full Text Ananta P, Kham-ngam I, Chetchotisakd P, et al. : Analysis of drug-susceptibility patterns and gene sequences associated with clarithromycin and amikacin resistance in serial Mycobacterium abscessus isolates from clinical specimens from Northeast Thailand. PLoS One. 2018; 13 : 1–15. Publisher Full Text Bastian S, Veziris N, Roux AL, et al. : Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob. Agents Chemother. 2011; 55 (2): 775–781. PubMed Abstract | Publisher Full Text Beverley Cherie Millar JEM: Antimycobacterial Strategies to Evade Antimicrobial Resistance in the Nontuberculous Mycobacteria. Int. J. Mycobacteriol. 2019; 8 (1): 7–21. PubMed Abstract | Publisher Full Text Bouzinbi N, Marcy O, Bertolotti T, et al. : Evaluation of the GenoType NTM-DR assay performance for the identification and molecular detection of antibiotic resistance in mycobacterium abscessus complex. PLoS One. 2020; 15 (9 September 2020): 1–5. PubMed Abstract | Publisher Full Text Brown-Elliott BA, Iakhiaeva E, Griffith DE, et al. : In vitro activity of amikacin against isolates of mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J. Clin. Microbiol. 2013; 51 (10): 3389–3394. PubMed Abstract | Publisher Full Text Brown-Elliott BA, Nash KA, Wallace RJ: Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin. Microbiol. Rev. 2012; 25 (3): 545–582. PubMed Abstract | Publisher Full Text Chalmers JD, Balavoine C, Castellotti PF, et al. : European Respiratory Society International Congress, Madrid, 2019: nontuberculous mycobacterial pulmonary disease highlights. Eur. Respir. J. 2019; 6 (May 2020): 00317–02020. PubMed Abstract | Publisher Full Text Falkinham JO: Environmental Sources of Non tuberculous Mycobacteria. Clin. Chest Med. 2017. Publisher Full Text Falkinham JO: Challenges of NTM drug development. Front. Microbiol. 2018; 9 (JUL): 1–7. PubMed Abstract | Publisher Full Text Gopalaswamy R, Shanmugam S, Mondal R, et al. : Of tuberculosis and non-tuberculous mycobacterial infections – a comparative analysis of epidemiology, diagnosis and treatment. J. Biomed. Sci. 2020; 27 : 17–74. PubMed Abstract | Publisher Full Text Goswami B, Narang P, Mishra P, et al. : Drug susceptibility of rapid and slow growing non-tuberculous mycobacteria isolated from symptomatics for pulmonary tuberculosis, Central India. Indian J. Med. Microbiol. 2016; 34 (4): 442–447. PubMed Abstract | Publisher Full Text Hansen JL, Ippolito JA, Ban N, et al. : The structures of four macrolide antibiotics bound to the large ribosomal subunit. Structural Insights into Gene Expression and Protein Synthesis. 2002; 10 : 117–128. Publisher Full Text Hoza AS, Mfinanga SGM, Rodloff AC, et al. : Increased isolation of nontuberculous mycobacteria among TB suspects in Northeastern, Tanzania: public health and diagnostic implications for control programmes. BMC. Res. Notes. 2016; 9 : 109. PubMed Abstract | Publisher Full Text Huh HJ, Kim SY, Jhun BW, et al. : Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Infect. Genet. Evol. 2019; 72 (October 2018): 169–182. PubMed Abstract | Publisher Full Text Kim SY, Kim DH, Moon SM, et al. : Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates. Sci. Rep. 2021; 11 (1): 6108–6108. PubMed Abstract | Publisher Full Text Klein JL, Brown TJ, French GL: Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob. Agents Chemother. 2001; 45 (11): 3056–3058. PubMed Abstract | Publisher Full Text Koh W, (2017). Nontuberculous Mycobacteria — Overview. Microbiology Spectrum , 1–7. Koh W, Kwon OJ, Jeon K, et al. : Clinical Significance of Nontuberculous Mycobacteria Isolated From Respiratory Specimens in Korea. Chest. 2006; 129 (2): 341–348. PubMed Abstract | Publisher Full Text Krause KM, Serio AW, Kane TR, Connolly LE: Aminoglycosides: An Overview.2016; 1–18. Li QJ, Jiao WW, Yin QQ, et al. : Compensatory mutations of rifampin resistance are associated with transmission of multidrug-resistant Mycobacterium tuberculosis Beijing genotype strains in China. Antimicrob. Agents Chemother. 2016; 60 (5): 2807–2812. PubMed Abstract | Publisher Full Text Litvinov V, Makarova M, Galkina K, et al. : Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system. PLoS One. 2018; 13 (9): e0203108–e0203113. PubMed Abstract | Publisher Full Text Munita JM, Arias CA: Mechanisms of antibiotic resistance. Virulence Mechanisms of Bacterial Pathogens. 2016; 4 (2): 481–511. Publisher Full Text Mwangi ZM, Mukiri N, Onyambu FG, et al. : Genetic Diversity of Nontuberculous Mycobacteria among Symptomatic Tuberculosis Negative Patients in Kenya. International Journal of Mycobacteriology. 2022a; 11 (1): 60–69. Publisher Full Text Mwangi Z, Onyambu F, Mureithi MW, et al. : Mutation Patterns of Resistance Genes for Macrolides, Aminoglycosides, and Rifampicin in Nontuberculous Mycobacteria Isolates from Kenya. figshare. Dataset. 2022b. Publisher Full Text Nasiri MJ, Haeili M, Ghazi M, et al. : New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria. Front. Microbiol. 2017; 8 (APR) Publisher Full Text Nessar R, Reyrat JM, Murray A, et al. : Genetic analysis of new 16s rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J. Antimicrob. Chemother. 2011; 66 (8): 1719–1724. PubMed Abstract | Publisher Full Text Olivier KN, Griffith DE, Eagle G, et al. : Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am. J. Respir. Crit. Care Med. 2017; 195 (6): 814–823. PubMed Abstract | Publisher Full Text Park HE, Kim S, Shim S, et al. : 16S and 23S Rrna Gene Mutation Independent Multidrug Resistance of Non-Tuberculous Mycobacteria Isolated From South Korean Soil. Microorganisms. 2020; 8 (8): 1–19. PubMed Abstract | Publisher Full Text Peixoto S, Maria L, Montenegro L, et al. : Major Article Identification of nontuberculous mycobacteria species by multiplex real-time PCR with high-resolution melting. Journal of the Brazilian Society of Tropical Medicine. 2020; 53 : 1–7. Publisher Full Text Pharmd JAS, Escalante P, Wilson JW: Pharmacotherapy Approaches in Nontuberculous Mycobacteria Infections Jennifer. Mayo Clin. Proc. 2019; 94 (August): 1567–1581. PubMed Abstract | Publisher Full Text Poehlsgaard J, Pfister P, Böttger E. C, et al. (2005). Molecular mechanisms by which rRNA mutations confer resistance to clindamycin. Antimicrobial Agents and Chemotherapy , 49 (4): 1553–1555. Publisher Full Text Pokam BDT, Yeboah-Manu D, Ofori S, et al. : Prevalence of non-tuberculous mycobacteria among previously treated TB patients in the Gulf of Guinea, Africa. IJID Regions. 2022; 3 (January): 287–292. PubMed Abstract | Publisher Full Text Ramasoota P, Pitaksajjakul P, Phatihattakorn W, et al. : Mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains from Thailand and its evolutionary implication. Southeast Asian J. Trop. Med. Public Health. 2006; 37 (1): 136–147. PubMed Abstract Rivero-Lezcano OM, Carolina González-Cortés MM: The Unexplained Increase of Nontuberculous Mycobacteriosis Octavio. Int. J. Mycobacteriol. 2019; 8 (1): 1–6. PubMed Abstract | Publisher Full Text Sam AS, Ninan MM, Ranjani R, et al. : Nontuberculous mycobacteria – clinical and laboratory diagnosis: experiences from a TB endemic country. Future Science OA. 2020; 6 . Publisher Full Text Sanz-García F, Anoz-Carbonell E, Pérez-Herrán E, et al. : Mycobacterial aminoglycoside acetyltransferases: A little of drug resistance, and a lot of other roles. Front. Microbiol. 2019; 10 (JAN): 1–11. PubMed Abstract | Publisher Full Text Saxena S, Spaink HP, Forn-Cuní G: Drug resistance in nontuberculous mycobacteria: Mechanisms and models. Biology. 2021; 10 (2): 1–22. PubMed Abstract | Publisher Full Text Simons S, Van Ingen J , Hsueh P, et al. : Nontuberculous Mycobacteria in Respiratory Tract Infections, Eastern Asia. Emerg. Infect. Dis. 2011; 17 (3). Publisher Full Text Tarashi S, Siadat SD, Fateh A: Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead. Biomed. Res. Int. 2022; 2022 : 1–12. PubMed Abstract | Publisher Full Text WHO: WHO guidelines for the programmatic management of drug-resistant tuberculosis.2014; (pp. 1–430). Reference Source Wu ML, Aziz DB, Dartois V, et al. : NTM drug discovery: status, gaps and the way forward. Drug Discov. Today. 2018; 23 (8): 1502–1519. PubMed Abstract | Publisher Full Text Zaragoza Bastida A, Rivero Pérez N, Valladares Carranza B, et al. : Molecular Identification of Mycobacterium Species of Public Health and Veterinary Importance from Cattle in the South State of México. Canadian Journal of Infectious Diseases and Medical Microbiology. 2017; 2017 : 4–11. PubMed Abstract | Publisher Full Text Zhou L, Xu D, Liu H, et al. : Trends in the Prevalence and Antibiotic Resistance of Non-tuberculous Mycobacteria in Mainland China, 2000–2019: Systematic Review and Meta-Analysis. Front. Public Health. 2020; 8 (July): 1–9. Publisher Full Text Comments on this article Comments (0) Version 5 VERSION 5 PUBLISHED 19 Aug 2022 ADD YOUR COMMENT Comment Author details Author details 1 Department of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Nairobi, 30197, Kenya 2 Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, Meru, 972, Kenya 3 Molecular and Infectious Disease Research Laboratory, University of Nairobi, Nairobi, Nairobi, 30197, Kenya 4 Centre for Molecular Biosciences and Genomics, Centre for Molecular Biosciences and Genomics, Nairobi, Nairobi, 29408, Kenya 5 Kenya Medical Research Institute, Kenya Medical Research Institute, Nairobi, Nairobi, 54840, Kenya Zakayo Mwangi Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing Grace Naeku Roles: Investigation, Writing – Review & Editing Marianne Mureithi Roles: Supervision, Writing – Review & Editing Frank Onyambu Roles: Conceptualization, Methodology, Supervision, Writing – Review & Editing Wallace Bulimo Roles: Conceptualization, Methodology, Supervision, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information This work was supported by the Meru University of Science and Technology 6th call for proposals awarded to Zakayo M Mwangi. The content is solely the responsibility of the authors and does not represent the views of the funders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (5) version 5 Revised Published: 03 Apr 2023, 11:962 https://doi.org/10.12688/f1000research.124002.5 version 4 Revised Published: 20 Feb 2023, 11:962 https://doi.org/10.12688/f1000research.124002.4 version 3 Revised Published: 05 Dec 2022, 11:962 https://doi.org/10.12688/f1000research.124002.3 version 2 Revised Published: 24 Oct 2022, 11:962 https://doi.org/10.12688/f1000research.124002.2 version 1 Published: 19 Aug 2022, 11:962 https://doi.org/10.12688/f1000research.124002.1 Copyright © 2023 Mwangi Z et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Mwangi Z, Naeku G, Mureithi M et al. Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.12688/f1000research.124002.5 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 5 VERSION 5 PUBLISHED 03 Apr 2023 Revised Views 0 Cite How to cite this report: Likhovole C. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.146329.r168595 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v5#referee-response-168595 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 04 Apr 2023 Clement Likhovole , Department of Microbiology, UZIMA University, Kisumu, Kenya Approved VIEWS 0 https://doi.org/10.5256/f1000research.146329.r168595 The authors have revised the manuscript as per the recommended ... Continue reading READ ALL The authors have revised the manuscript as per the recommended changes. The revised manuscript is adequate in form and content Competing Interests: No competing interests were disclosed. Reviewer Expertise: TB molecular biology and immunology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Likhovole C. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.146329.r168595 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v5#referee-response-168595 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 05 Apr 2023 Zakayo Mwangi , Meru University of Science and Technology, Kenya 05 Apr 2023 Author Response Thank you for your approval Competing Interests: No competing interests were disclosed. Thank you for your approval Thank you for your approval Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 05 Apr 2023 Zakayo Mwangi , Meru University of Science and Technology, Kenya 05 Apr 2023 Author Response Thank you for your approval Competing Interests: No competing interests were disclosed. Thank you for your approval Thank you for your approval Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Version 4 VERSION 4 PUBLISHED 20 Feb 2023 Revised Views 0 Cite How to cite this report: Likhovole C. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.144441.r167243 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v4#referee-response-167243 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 24 Mar 2023 Clement Likhovole , Department of Microbiology, UZIMA University, Kisumu, Kenya Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.144441.r167243 General comments The manuscript addresses an important area in Tuberculosis research particularly analysis of drug resistant mutations that have been linked to treatment failure. Abstract: The authors to include a ... Continue reading READ ALL General comments The manuscript addresses an important area in Tuberculosis research particularly analysis of drug resistant mutations that have been linked to treatment failure. Abstract: The authors to include a hyphen in Non-tuberculous Mycobacterium (NTM). Use upper case for the first letters of the following acronyms, SGM and RGM. In the results section, percentages should not be in brackets. The proportions to indicated in brackets e.g. 23% (23/100). This should be done all the data presented in this section. When reporting on the mutations, also indicate the amino acid or nucleotide change as well. For example, which mutation is present on codon 2058? Change from what to what? Introduction: Second sentence, the authors to describe in detail the type of culture used to grow NTMs for 40 days. MGIT? Second paragraph, authors to indicate the duration of treatment of NTM infections. Also the length of treatment with Rifampicin to be mentioned. Is it the same for patients infected with comorbidities? The authors have listed several drugs used for the treatment of NTMs but described only one resistance mechanisms for NTMs, do they all have the same type of resistance mechanism? (Macrolides - Clarithromycon and Azithromycin). Paragraph seven, the authors to indicate that Rifampicin is recommended for first-line treatment of MTB alongside other drugs. Laboratory procedures: The authors to estimate the volume of sputum sample collected from each participant. For the FM microscopy, how many readers were used before reporting the smear results? What volume of DNA was finally collected after extraction? Was quantification of the DNA material done? Results: The authors to mention the table with results indicating that the bulk of the samples were obtained from Lake Victoria, Coastal and Nairobi region. Discussion: The authors to refer to my previous comments on Non-tuberculous mycobacterium. The authors to critically discuss the relevance of the rrl significant mutations reported in the study sites. What are the implications of these finding? Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: TB molecular biology and immunology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Likhovole C. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.144441.r167243 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v4#referee-response-167243 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 29 Mar 2023 Zakayo Mwangi , Meru University of Science and Technology, Kenya 29 Mar 2023 Author Response Thank you for your valuable feedback. Competing Interests: No competing interests were disclosed. Thank you for your valuable feedback. Thank you for your valuable feedback. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 29 Mar 2023 Zakayo Mwangi , Meru University of Science and Technology, Kenya 29 Mar 2023 Author Response Thank you for your valuable feedback. Competing Interests: No competing interests were disclosed. Thank you for your valuable feedback. Thank you for your valuable feedback. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Al-Hassan L. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.144441.r163993 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v4#referee-response-163993 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 27 Feb 2023 Leena Al-Hassan , Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK Not Approved VIEWS 0 https://doi.org/10.5256/f1000research.144441.r163993 No further comments. Please see previous comments ... Continue reading READ ALL No further comments. Please see previous comments about the need to correlate findings with MIC. Competing Interests: No competing interests were disclosed. Reviewer Expertise: Infectious diseases and antibiotic resistance I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Al-Hassan L. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.144441.r163993 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v4#referee-response-163993 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Version 3 VERSION 3 PUBLISHED 05 Dec 2022 Revised Views 0 Cite How to cite this report: Al-Hassan L. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.141647.r157361 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v3#referee-response-157361 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 05 Dec 2022 Leena Al-Hassan , Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK Not Approved VIEWS 0 https://doi.org/10.5256/f1000research.141647.r157361 I have read the revised version, but I still see that the manuscript has misleading information that needs to be re-written. The data provided need to associated with phenotypic data on resistance. Identification of mutations in genes is not sufficient ... Continue reading READ ALL I have read the revised version, but I still see that the manuscript has misleading information that needs to be re-written. The data provided need to associated with phenotypic data on resistance. Identification of mutations in genes is not sufficient to prove resistance, as the researchers have not confirmed any silent mutations. The positive controls used in the methodology should be isolates that are confirmed resistant and harbour these mutations. This is the definition of a positive control. The negative control is an isolates that is genotypically confirmed having no mutations in the target genes. Competing Interests: No competing interests were disclosed. Reviewer Expertise: Infectious diseases and antibiotic resistance I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Al-Hassan L. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.141647.r157361 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v3#referee-response-157361 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 15 Dec 2022 Zakayo Mwangi , Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya 15 Dec 2022 Author Response Thank you for the feedback. Competing Interests: No competing interests were disclosed. Thank you for the feedback. Thank you for the feedback. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 15 Dec 2022 Zakayo Mwangi , Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya 15 Dec 2022 Author Response Thank you for the feedback. Competing Interests: No competing interests were disclosed. Thank you for the feedback. Thank you for the feedback. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Version 2 VERSION 2 PUBLISHED 24 Oct 2022 Revised Views 0 Cite How to cite this report: Al-Hassan L. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.139953.r154017 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v2#referee-response-154017 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 22 Nov 2022 Leena Al-Hassan , Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK Not Approved VIEWS 0 https://doi.org/10.5256/f1000research.139953.r154017 Thank you for revising the manuscript and incorporating the comments into the text. However I would highly suggest that you revise the sections where you correlate the genotype with phenotype, since you have not done the AST (MIC) in this ... Continue reading READ ALL Thank you for revising the manuscript and incorporating the comments into the text. However I would highly suggest that you revise the sections where you correlate the genotype with phenotype, since you have not done the AST (MIC) in this study. If you have not done the AST testing, you cannot state that they are resistant. Your study is primarily genotype based, and you have detected mutations in target resistance determinants, and I therefore suggest you change the wording of the results and discussion to reflect that. These mutations may be silent mutations, and if you do not have phenotype data to support it, you cannot state the fact that they are resistant. You can only say that they harbour the mutations which in previous reports have led to resistance. These statements "Twenty-eight (23%) of the NTM were resistant to at least one of the antibiotics used in the macrolide-based treatment " and "Ten (14.7%) of the 68 SGM were resistant to rifampicin, with 40 percent having mutations at codon 531 in the rpoB gene" cannot be proven without AST. You should re-word it to say that 23% harboured mutations associated with resistance to macrolide antibiotics. Same for the conclusion: you have not demonstrated a significant level of drug resistance for macrolides, aminoglycosides and rifampicin in NTM - you have detected mutations in gene targets that have previously been associated with drug resistance. I hope my point is clear. I am not doubting your results, and I think it's interesting that you have detected these mutations, however it's not scientifically sound to assume resistance based on genotype only, and you must phrase your results and conclusions according to the methods used and data generated. The way it is written now indicates that you have the AST data for the isolates and you are sure that they are rifampicin or aminoglycoside resistant. I would strongly recommend you perform the AST - even for a subset of isolates - to confirm that the observed genotype correlates with the phenotype. Competing Interests: No competing interests were disclosed. Reviewer Expertise: Infectious diseases and antibiotic resistance I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Al-Hassan L. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.139953.r154017 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v2#referee-response-154017 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 05 Dec 2022 Zakayo Mwangi , Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya 05 Dec 2022 Author Response I appreciate your re-evaluation and the way in which you made the issues that need to be addressed evident. I revised the paper in accordance with your advice and ... Continue reading I appreciate your re-evaluation and the way in which you made the issues that need to be addressed evident. I revised the paper in accordance with your advice and resubmitted it for review. I appreciate your re-evaluation and the way in which you made the issues that need to be addressed evident. I revised the paper in accordance with your advice and resubmitted it for review. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 05 Dec 2022 Zakayo Mwangi , Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya 05 Dec 2022 Author Response I appreciate your re-evaluation and the way in which you made the issues that need to be addressed evident. I revised the paper in accordance with your advice and ... Continue reading I appreciate your re-evaluation and the way in which you made the issues that need to be addressed evident. I revised the paper in accordance with your advice and resubmitted it for review. I appreciate your re-evaluation and the way in which you made the issues that need to be addressed evident. I revised the paper in accordance with your advice and resubmitted it for review. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Sengupta U. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.139953.r154016 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v2#referee-response-154016 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 03 Nov 2022 Utpal Sengupta , Stanley Browne Laboratory, The Leprosy Mission Community Hospital, New Delhi, Delhi, India Approved VIEWS 0 https://doi.org/10.5256/f1000research.139953.r154016 The manuscript can ... Continue reading READ ALL The manuscript can be accepted now. Competing Interests: No competing interests were disclosed. Reviewer Expertise: Infectious diseases with special reference to tuberculosis and leprosy, Cell Biology, Microbiology, Immunology and Biotechnology. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Sengupta U. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.139953.r154016 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v2#referee-response-154016 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 05 Dec 2022 Zakayo Mwangi , Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya 05 Dec 2022 Author Response We sincerely appreciate your second reading and approval. Competing Interests: No competing interests were disclosed. We sincerely appreciate your second reading and approval. We sincerely appreciate your second reading and approval. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 05 Dec 2022 Zakayo Mwangi , Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya 05 Dec 2022 Author Response We sincerely appreciate your second reading and approval. Competing Interests: No competing interests were disclosed. We sincerely appreciate your second reading and approval. We sincerely appreciate your second reading and approval. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Version 1 VERSION 1 PUBLISHED 19 Aug 2022 Views 0 Cite How to cite this report: Sengupta U. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.136168.r150334 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v1#referee-response-150334 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 10 Oct 2022 Utpal Sengupta , Stanley Browne Laboratory, The Leprosy Mission Community Hospital, New Delhi, Delhi, India Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.136168.r150334 The manuscript has been written on the findings of antimycobacterial resistance of NTM isolated from 122 sputum M. tuberculosis -negative patients. The authors have investigated their resistance patterns on the isolated strains using gene sequencing of the drug-resistant genes and noted ... Continue reading READ ALL The manuscript has been written on the findings of antimycobacterial resistance of NTM isolated from 122 sputum M. tuberculosis -negative patients. The authors have investigated their resistance patterns on the isolated strains using gene sequencing of the drug-resistant genes and noted the mutations in the respective codon positions. Materials and methods have been well described. Data were properly analyzed and presented adequately in the tables. However, there were a lot of discrepancies in Table 2 in the first column where the total sample number was shown to be 135 instead of 122 and therefore the percentage expressions were wrongly mentioned in the table and in the text. The percentages have to be calculated correctly and Table 2 has to be modified and described accordingly in the text. The discussion has been adequate, citing adequate references. However, the discussion with respect to the results of Table 2 has to be modified and discussed for a correct understanding of the reader. Is the work clearly and accurately presented and does it cite the current literature? Partly Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Infectious diseases with special reference to tuberculosis and leprosy, Cell Biology, Microbiology, Immunology and Biotechnology. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Sengupta U. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.136168.r150334 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v1#referee-response-150334 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 24 Oct 2022 Zakayo Mwangi , Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya 24 Oct 2022 Author Response I appreciate your review. The issue mentioned above has been addressed. Competing Interests: No competing interests were disclosed. I appreciate your review. The issue mentioned above has been addressed. I appreciate your review. The issue mentioned above has been addressed. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 24 Oct 2022 Zakayo Mwangi , Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya 24 Oct 2022 Author Response I appreciate your review. The issue mentioned above has been addressed. Competing Interests: No competing interests were disclosed. I appreciate your review. The issue mentioned above has been addressed. I appreciate your review. The issue mentioned above has been addressed. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Al-Hassan L. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.136168.r148288 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v1#referee-response-148288 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 22 Sep 2022 Leena Al-Hassan , Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.136168.r148288 This study characterises mutation patterns for resistance genes in NTM from Kenya. Although the study is interesting, I think the authors need to give more information in the methodology and results section on: ... Continue reading READ ALL This study characterises mutation patterns for resistance genes in NTM from Kenya. Although the study is interesting, I think the authors need to give more information in the methodology and results section on: Identification: 122 isolates were collected, but no details in the results on how many were slow-growing and rapid-growing NTM. MIC: No mention of methodology for MIC and results. The PCR: Did you include any positive or negative controls in the experiments? The discussion on mutations and their role in resistance is quite vague. It's not clear whether the mutations identified can be linked to the observed MIC. Have the researchers checked that these are not silent mutations? Is the work clearly and accurately presented and does it cite the current literature? Partly Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Partly If applicable, is the statistical analysis and its interpretation appropriate? I cannot comment. A qualified statistician is required. Are all the source data underlying the results available to ensure full reproducibility? Partly Are the conclusions drawn adequately supported by the results? Partly Competing Interests: No competing interests were disclosed. Reviewer Expertise: Infectious diseases and antibiotic resistance I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Al-Hassan L. Reviewer Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.136168.r148288 ) The direct URL for this report is: https://f1000research.com/articles/11-962/v1#referee-response-148288 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 06 Oct 2022 Zakayo Mwangi , Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya 06 Oct 2022 Author Response I appreciate your review. Under methods, it has been indicated that of the 122 NTM isolated, 54 were rapid-growing NTM while 68 were slow-growing NTM. ... Continue reading I appreciate your review. Under methods, it has been indicated that of the 122 NTM isolated, 54 were rapid-growing NTM while 68 were slow-growing NTM. The phenotypic drug sensitivity by MIC analysis was not done in this study. We performed genotypic characterization of the drug target genes by describing the mutations associated with drug resistance through target sequencing of the drug target genes. Positive and negative controls were included during PCR and subsequent sequencing of respective target genes. The controls were based on Genotype NTM-DR results. In the discussion, the mutations identified in this study have been compared to those seen in previous studies that had also included MIC in their analysis. The point mutations identified in the drug target genes were seen to be associated with phenotypic drug resistance. I appreciate your review. Under methods, it has been indicated that of the 122 NTM isolated, 54 were rapid-growing NTM while 68 were slow-growing NTM. The phenotypic drug sensitivity by MIC analysis was not done in this study. We performed genotypic characterization of the drug target genes by describing the mutations associated with drug resistance through target sequencing of the drug target genes. Positive and negative controls were included during PCR and subsequent sequencing of respective target genes. The controls were based on Genotype NTM-DR results. In the discussion, the mutations identified in this study have been compared to those seen in previous studies that had also included MIC in their analysis. The point mutations identified in the drug target genes were seen to be associated with phenotypic drug resistance. Competing Interests: No competing interests Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 06 Oct 2022 Zakayo Mwangi , Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya 06 Oct 2022 Author Response I appreciate your review. Under methods, it has been indicated that of the 122 NTM isolated, 54 were rapid-growing NTM while 68 were slow-growing NTM. ... Continue reading I appreciate your review. Under methods, it has been indicated that of the 122 NTM isolated, 54 were rapid-growing NTM while 68 were slow-growing NTM. The phenotypic drug sensitivity by MIC analysis was not done in this study. We performed genotypic characterization of the drug target genes by describing the mutations associated with drug resistance through target sequencing of the drug target genes. Positive and negative controls were included during PCR and subsequent sequencing of respective target genes. The controls were based on Genotype NTM-DR results. In the discussion, the mutations identified in this study have been compared to those seen in previous studies that had also included MIC in their analysis. The point mutations identified in the drug target genes were seen to be associated with phenotypic drug resistance. I appreciate your review. Under methods, it has been indicated that of the 122 NTM isolated, 54 were rapid-growing NTM while 68 were slow-growing NTM. The phenotypic drug sensitivity by MIC analysis was not done in this study. We performed genotypic characterization of the drug target genes by describing the mutations associated with drug resistance through target sequencing of the drug target genes. Positive and negative controls were included during PCR and subsequent sequencing of respective target genes. The controls were based on Genotype NTM-DR results. In the discussion, the mutations identified in this study have been compared to those seen in previous studies that had also included MIC in their analysis. The point mutations identified in the drug target genes were seen to be associated with phenotypic drug resistance. Competing Interests: No competing interests Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 5 VERSION 5 PUBLISHED 19 Aug 2022 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 3 Version 5 (revision) 03 Apr 23 read Version 4 (revision) 20 Feb 23 read read Version 3 (revision) 05 Dec 22 read Version 2 (revision) 24 Oct 22 read read Version 1 19 Aug 22 read read Leena Al-Hassan , Brighton and Sussex Medical School, Brighton, UK Utpal Sengupta , The Leprosy Mission Community Hospital, New Delhi, India Clement Likhovole , UZIMA University, Kisumu, Kenya Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2023 Likhovole C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 04 Apr 2023 | for Version 5 Clement Likhovole , Department of Microbiology, UZIMA University, Kisumu, Kenya 0 Views copyright © 2023 Likhovole C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The authors have revised the manuscript as per the recommended changes. The revised manuscript is adequate in form and content Competing Interests No competing interests were disclosed. Reviewer Expertise TB molecular biology and immunology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 05 Apr 2023 Zakayo Mwangi, Meru University of Science and Technology, Kenya Thank you for your approval View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Likhovole C. Peer Review Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.146329.r168595) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-962/v5#referee-response-168595 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2023 Likhovole C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 24 Mar 2023 | for Version 4 Clement Likhovole , Department of Microbiology, UZIMA University, Kisumu, Kenya 0 Views copyright © 2023 Likhovole C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions General comments The manuscript addresses an important area in Tuberculosis research particularly analysis of drug resistant mutations that have been linked to treatment failure. Abstract: The authors to include a hyphen in Non-tuberculous Mycobacterium (NTM). Use upper case for the first letters of the following acronyms, SGM and RGM. In the results section, percentages should not be in brackets. The proportions to indicated in brackets e.g. 23% (23/100). This should be done all the data presented in this section. When reporting on the mutations, also indicate the amino acid or nucleotide change as well. For example, which mutation is present on codon 2058? Change from what to what? Introduction: Second sentence, the authors to describe in detail the type of culture used to grow NTMs for 40 days. MGIT? Second paragraph, authors to indicate the duration of treatment of NTM infections. Also the length of treatment with Rifampicin to be mentioned. Is it the same for patients infected with comorbidities? The authors have listed several drugs used for the treatment of NTMs but described only one resistance mechanisms for NTMs, do they all have the same type of resistance mechanism? (Macrolides - Clarithromycon and Azithromycin). Paragraph seven, the authors to indicate that Rifampicin is recommended for first-line treatment of MTB alongside other drugs. Laboratory procedures: The authors to estimate the volume of sputum sample collected from each participant. For the FM microscopy, how many readers were used before reporting the smear results? What volume of DNA was finally collected after extraction? Was quantification of the DNA material done? Results: The authors to mention the table with results indicating that the bulk of the samples were obtained from Lake Victoria, Coastal and Nairobi region. Discussion: The authors to refer to my previous comments on Non-tuberculous mycobacterium. The authors to critically discuss the relevance of the rrl significant mutations reported in the study sites. What are the implications of these finding? Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise TB molecular biology and immunology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 29 Mar 2023 Zakayo Mwangi, Meru University of Science and Technology, Kenya Thank you for your valuable feedback. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Likhovole C. Peer Review Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.144441.r167243) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-962/v4#referee-response-167243 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2023 Al-Hassan L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 27 Feb 2023 | for Version 4 Leena Al-Hassan , Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK 0 Views copyright © 2023 Al-Hassan L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Not Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions No further comments. Please see previous comments about the need to correlate findings with MIC. Competing Interests No competing interests were disclosed. Reviewer Expertise Infectious diseases and antibiotic resistance I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. reply Respond to this report Responses (0) Al-Hassan L. Peer Review Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.144441.r163993) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-962/v4#referee-response-163993 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2022 Al-Hassan L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 05 Dec 2022 | for Version 3 Leena Al-Hassan , Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK 0 Views copyright © 2022 Al-Hassan L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Not Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions I have read the revised version, but I still see that the manuscript has misleading information that needs to be re-written. The data provided need to associated with phenotypic data on resistance. Identification of mutations in genes is not sufficient to prove resistance, as the researchers have not confirmed any silent mutations. The positive controls used in the methodology should be isolates that are confirmed resistant and harbour these mutations. This is the definition of a positive control. The negative control is an isolates that is genotypically confirmed having no mutations in the target genes. Competing Interests No competing interests were disclosed. Reviewer Expertise Infectious diseases and antibiotic resistance I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. reply Respond to this report Responses (1) Author Response 15 Dec 2022 Zakayo Mwangi, Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya Thank you for the feedback. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Al-Hassan L. Peer Review Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.141647.r157361) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-962/v3#referee-response-157361 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2022 Al-Hassan L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 22 Nov 2022 | for Version 2 Leena Al-Hassan , Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK 0 Views copyright © 2022 Al-Hassan L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Not Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Thank you for revising the manuscript and incorporating the comments into the text. However I would highly suggest that you revise the sections where you correlate the genotype with phenotype, since you have not done the AST (MIC) in this study. If you have not done the AST testing, you cannot state that they are resistant. Your study is primarily genotype based, and you have detected mutations in target resistance determinants, and I therefore suggest you change the wording of the results and discussion to reflect that. These mutations may be silent mutations, and if you do not have phenotype data to support it, you cannot state the fact that they are resistant. You can only say that they harbour the mutations which in previous reports have led to resistance. These statements "Twenty-eight (23%) of the NTM were resistant to at least one of the antibiotics used in the macrolide-based treatment " and "Ten (14.7%) of the 68 SGM were resistant to rifampicin, with 40 percent having mutations at codon 531 in the rpoB gene" cannot be proven without AST. You should re-word it to say that 23% harboured mutations associated with resistance to macrolide antibiotics. Same for the conclusion: you have not demonstrated a significant level of drug resistance for macrolides, aminoglycosides and rifampicin in NTM - you have detected mutations in gene targets that have previously been associated with drug resistance. I hope my point is clear. I am not doubting your results, and I think it's interesting that you have detected these mutations, however it's not scientifically sound to assume resistance based on genotype only, and you must phrase your results and conclusions according to the methods used and data generated. The way it is written now indicates that you have the AST data for the isolates and you are sure that they are rifampicin or aminoglycoside resistant. I would strongly recommend you perform the AST - even for a subset of isolates - to confirm that the observed genotype correlates with the phenotype. Competing Interests No competing interests were disclosed. Reviewer Expertise Infectious diseases and antibiotic resistance I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. reply Respond to this report Responses (1) Author Response 05 Dec 2022 Zakayo Mwangi, Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya I appreciate your re-evaluation and the way in which you made the issues that need to be addressed evident. I revised the paper in accordance with your advice and resubmitted it for review. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Al-Hassan L. Peer Review Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.139953.r154017) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-962/v2#referee-response-154017 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2022 Sengupta U. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 03 Nov 2022 | for Version 2 Utpal Sengupta , Stanley Browne Laboratory, The Leprosy Mission Community Hospital, New Delhi, Delhi, India 0 Views copyright © 2022 Sengupta U. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The manuscript can be accepted now. Competing Interests No competing interests were disclosed. Reviewer Expertise Infectious diseases with special reference to tuberculosis and leprosy, Cell Biology, Microbiology, Immunology and Biotechnology. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 05 Dec 2022 Zakayo Mwangi, Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya We sincerely appreciate your second reading and approval. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Sengupta U. Peer Review Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.139953.r154016) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-962/v2#referee-response-154016 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2022 Sengupta U. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 10 Oct 2022 | for Version 1 Utpal Sengupta , Stanley Browne Laboratory, The Leprosy Mission Community Hospital, New Delhi, Delhi, India 0 Views copyright © 2022 Sengupta U. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The manuscript has been written on the findings of antimycobacterial resistance of NTM isolated from 122 sputum M. tuberculosis -negative patients. The authors have investigated their resistance patterns on the isolated strains using gene sequencing of the drug-resistant genes and noted the mutations in the respective codon positions. Materials and methods have been well described. Data were properly analyzed and presented adequately in the tables. However, there were a lot of discrepancies in Table 2 in the first column where the total sample number was shown to be 135 instead of 122 and therefore the percentage expressions were wrongly mentioned in the table and in the text. The percentages have to be calculated correctly and Table 2 has to be modified and described accordingly in the text. The discussion has been adequate, citing adequate references. However, the discussion with respect to the results of Table 2 has to be modified and discussed for a correct understanding of the reader. Is the work clearly and accurately presented and does it cite the current literature? Partly Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Infectious diseases with special reference to tuberculosis and leprosy, Cell Biology, Microbiology, Immunology and Biotechnology. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 24 Oct 2022 Zakayo Mwangi, Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya I appreciate your review. The issue mentioned above has been addressed. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Sengupta U. Peer Review Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.136168.r150334) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-962/v1#referee-response-150334 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2022 Al-Hassan L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 22 Sep 2022 | for Version 1 Leena Al-Hassan , Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK 0 Views copyright © 2022 Al-Hassan L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This study characterises mutation patterns for resistance genes in NTM from Kenya. Although the study is interesting, I think the authors need to give more information in the methodology and results section on: Identification: 122 isolates were collected, but no details in the results on how many were slow-growing and rapid-growing NTM. MIC: No mention of methodology for MIC and results. The PCR: Did you include any positive or negative controls in the experiments? The discussion on mutations and their role in resistance is quite vague. It's not clear whether the mutations identified can be linked to the observed MIC. Have the researchers checked that these are not silent mutations? Is the work clearly and accurately presented and does it cite the current literature? Partly Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Partly If applicable, is the statistical analysis and its interpretation appropriate? I cannot comment. A qualified statistician is required. Are all the source data underlying the results available to ensure full reproducibility? Partly Are the conclusions drawn adequately supported by the results? Partly Competing Interests No competing interests were disclosed. Reviewer Expertise Infectious diseases and antibiotic resistance I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 06 Oct 2022 Zakayo Mwangi, Department of Medical Laboratory Science, Meru University of Science and Technology, Meru, 972, Kenya I appreciate your review. Under methods, it has been indicated that of the 122 NTM isolated, 54 were rapid-growing NTM while 68 were slow-growing NTM. The phenotypic drug sensitivity by MIC analysis was not done in this study. We performed genotypic characterization of the drug target genes by describing the mutations associated with drug resistance through target sequencing of the drug target genes. Positive and negative controls were included during PCR and subsequent sequencing of respective target genes. The controls were based on Genotype NTM-DR results. In the discussion, the mutations identified in this study have been compared to those seen in previous studies that had also included MIC in their analysis. The point mutations identified in the drug target genes were seen to be associated with phenotypic drug resistance. View more View less Competing Interests No competing interests reply Respond Report a concern Al-Hassan L. Peer Review Report For: Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya [version 5; peer review: 2 approved, 1 not approved] . F1000Research 2023, 11 :962 ( https://doi.org/10.5256/f1000research.136168.r148288) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-962/v1#referee-response-148288 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Mutation patterns of resistance genes for...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/11-962/v5" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/11-962/v5&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/11-962/v5" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Mwangi Z et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/11-962/v5/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/11-962", templates : { twitter : "Mutation patterns of resistance genes for macrolides, aminoglycosides,.... Mwangi Z et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/11-962/v5" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/124002/146329") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "146329"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "148290": 0, "150338": 0, "148291": 0, "150336": 0, "148288": 57, "148289": 0, "150337": 0, "148292": 0, "167243": 18, "168594": 0, "168595": 10, "168596": 0, "164123": 0, "163992": 0, "163993": 25, "149977": 0, "155298": 0, "154016": 29, "154017": 32, "157362": 0, "157361": 41, "148286": 0, "150334": 25, "148287": 0, "150335": 0, "150333": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "c7d366d4-1a78-494f-945b-ebffe682b66b"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });